Document is current
Any future updates will be listed below
-
Authors
Robbins, Charles J. https://orcid.org/0000-0002-3130-7107
Bates, Katherine M. https://orcid.org/0000-0001-8956-6331
Rimm, David L. https://orcid.org/0000-0001-5820-4397
- License Information
-
More Information
Article History
Accepted: 13 March 2025
First Online: 7 April 2025
Competing interests
: D.L.R. has acted as an advisor of Agendia, Amgen, AstraZeneca, Bristol Myers Squibb, Cell Signalling Technology, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, GSK, Halda Biotherapeutics, Incendia, Konica Minolta, Merck, NanoString, Nucleai, PAIGE.AI, Perkin Elmer, Regeneron, Roche, Sanofi, and Ventana and has received research funding from Amgen, Cepheid, Konica Minolta, Leica, NavigateBP and NextCure. The other authors declare no competing interests.
